WuXi Biologics (WXXWY) Financial Analysis & Valuation | Quarter Chart
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the bio... more
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, dev... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $28.64B | Exchange | OTC |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CN | CEO | Zhisheng Chen |
| IPO Date | 2017-12-18 | CAGR | 45.92% |
| Employees | 13,252 | Website | www.wuxibiologics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 7.43% | Total Yield | 7.43% |
WXXWY chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $119.21B | P/E | 39.56 | Forward P/E | — | PEG | 9.27 |
| P/S | 9.64 | P/B | 4.66 | P/CF | 34.87 | P/FCF | 83.78 |
| Sales | $6.45B | Sales 1Y | 28.69% | Sales 3Y | 484.91% | Sales 5Y | 3724% |
| EPS | $0.35 | EPS 1Y | 37.82% | EPS 3Y | 309.52% | EPS 5Y | 4635.68% |
| Sales QoQ | 0.34% | EPS QoQ | -1.69% | Sales QoQ Avg | 8.35% | EPS QoQ Avg | 14.09% |
| Gross Margin | 47.48% | Operating Margin | 32.36% | Profit Margin | 21.21% | ROCE | 13.28% |
| ROA | 8% | ROE | 10% | Altman Z Score | 11.64 | Piotroski Score | 9 |
| Current Ratio | 3.04 | Quick Ratio | 2.82 | Cash Ratio | 1.09 | Op. CF Ratio | 0.56 |
| Debt/Equity | 0.05 | Debt/Assets | 0.04 | Lt Debt/Equity | 0.04 | Lt Debt/Cap. | — |
| Intrst Cov. | 74.09 | Inventory Turnover | 6.76 | Asset Turnover | 0.36 | Receivables Turnover | 2.73 |
| Enterprise Value | $119.21B | P/E Ratio | 39.56 |
| Forward P/E | — | PEG Ratio | 9.27 |
| P/S Ratio | 9.64 | P/B Ratio | 4.66 |
| P/CF Ratio | 34.87 | P/FCF Ratio | 83.78 |
| EPS | $0.35 | EPS Growth 1Y | 37.82% |
| EPS Growth 3Y | 309.52% | EPS Growth 5Y | 4635.68% |
| Revenue Growth 1Y | 28.69% | Gross Margin | 47.48% |
| Operating Margin | 32.36% | Profit Margin | 21.21% |
| ROE | 10% | ROA | 8% |
| ROCE | 13.28% | Current Ratio | 3.04 |
| Quick Ratio | 2.82 | Cash Ratio | 1.09 |
| Debt/Equity | 0.05 | Interest Coverage | 74.09 |
| Altman Z Score | 11.64 | Piotroski Score | 9 |
WuXi Biologics (WXXWY) valuation & financials
WuXi Biologics (WXXWY) has a market capitalization of $28.64B and trades at a price-to-earnings ratio of 39.6. It operates in the Healthcare sector (Biotechnology).
WuXi Biologics's revenue grew +28.7% over the last year.
WuXi Biologics's next earnings report is scheduled for March 23, 2027 (provider scheduled date); analysts estimate EPS of $0.13. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)